Amgen Inc. (NASDAQ:AMGN) Shares Purchased by HB Wealth Management LLC

HB Wealth Management LLC increased its position in shares of Amgen Inc. (NASDAQ:AMGNGet Rating) by 14.8% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 25,036 shares of the medical research company’s stock after acquiring an additional 3,234 shares during the period. HB Wealth Management LLC’s holdings in Amgen were worth $6,091,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. Ritholtz Wealth Management raised its holdings in shares of Amgen by 11.6% in the second quarter. Ritholtz Wealth Management now owns 12,866 shares of the medical research company’s stock worth $3,130,000 after acquiring an additional 1,334 shares during the last quarter. Five Oceans Advisors lifted its holdings in shares of Amgen by 5.3% during the 2nd quarter. Five Oceans Advisors now owns 1,093 shares of the medical research company’s stock worth $266,000 after acquiring an additional 55 shares during the period. Miracle Mile Advisors LLC boosted its position in shares of Amgen by 181.0% in the second quarter. Miracle Mile Advisors LLC now owns 3,130 shares of the medical research company’s stock worth $761,000 after acquiring an additional 2,016 shares during the last quarter. PDS Planning Inc boosted its position in shares of Amgen by 25.2% in the second quarter. PDS Planning Inc now owns 1,266 shares of the medical research company’s stock worth $308,000 after acquiring an additional 255 shares during the last quarter. Finally, IFM Investors Pty Ltd boosted its position in shares of Amgen by 7.2% in the second quarter. IFM Investors Pty Ltd now owns 96,136 shares of the medical research company’s stock worth $23,390,000 after acquiring an additional 6,437 shares during the last quarter. 77.14% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Performance

AMGN stock traded down $2.20 during trading hours on Friday, hitting $225.55. 47,623 shares of the stock were exchanged, compared to its average volume of 2,761,167. The company has a current ratio of 1.53, a quick ratio of 1.17 and a debt-to-equity ratio of 14.76. Amgen Inc. has a 12 month low of $198.64 and a 12 month high of $258.45. The firm has a market capitalization of $120.65 billion, a P/E ratio of 19.11, a P/E/G ratio of 1.81 and a beta of 0.56. The company has a 50-day simple moving average of $243.40 and a two-hundred day simple moving average of $243.35.

Amgen (NASDAQ:AMGNGet Rating) last announced its quarterly earnings results on Thursday, August 4th. The medical research company reported $4.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.40 by $0.25. Amgen had a net margin of 24.92% and a return on equity of 218.34%. The firm had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.53 billion. During the same period in the prior year, the company posted $4.38 EPS. The company’s revenue was up 1.0% on a year-over-year basis. On average, analysts forecast that Amgen Inc. will post 17.45 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Thursday, August 18th were issued a dividend of $1.94 per share. This represents a $7.76 dividend on an annualized basis and a dividend yield of 3.44%. The ex-dividend date of this dividend was Wednesday, August 17th. Amgen’s dividend payout ratio is currently 65.76%.

Insider Activity at Amgen

In other Amgen news, Director R Sanders Williams sold 200 shares of Amgen stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $249.96, for a total value of $49,992.00. Following the sale, the director now owns 5,301 shares of the company’s stock, valued at $1,325,037.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Amgen news, Director Robert Eckert sold 6,600 shares of Amgen stock in a transaction dated Thursday, August 18th. The shares were sold at an average price of $249.00, for a total value of $1,643,400.00. Following the sale, the director now owns 21,184 shares of the company’s stock, valued at $5,274,816. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director R Sanders Williams sold 200 shares of Amgen stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $249.96, for a total transaction of $49,992.00. Following the completion of the transaction, the director now owns 5,301 shares of the company’s stock, valued at $1,325,037.96. The disclosure for this sale can be found here. 0.46% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. StockNews.com lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 8th. Robert W. Baird reaffirmed an “underperform” rating and issued a $185.00 price objective on shares of Amgen in a report on Tuesday, September 13th. TheStreet raised shares of Amgen from a “c+” rating to a “b” rating in a report on Monday, August 15th. Atlantic Securities reduced their price target on shares of Amgen from $190.00 to $182.00 and set an “underweight” rating for the company in a research note on Tuesday, August 9th. Finally, Morgan Stanley raised their price objective on shares of Amgen from $239.00 to $253.00 and gave the company an “equal weight” rating in a research note on Friday, July 15th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $241.13.

Amgen Profile

(Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

See Also

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNGet Rating).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.